Cited by 459Phagocytosis and Immune RegulationCell death mechanisms and regulationAutophagy in Disease and Therapy

Drugging the efferocytosis process: concepts and opportunities

Open access
Mehrotra, Parul, Ravichandran, Kodi S.·2022·Nature Reviews Drug Discovery

Abstract

The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer volume of cell turnover, efferocytosis is a point of vulnerability. Aberrations in efferocytosis are associated with numerous inflammatory pathologies, including atherosclerosis, cancer and infections. The recent exciting discoveries defining the molecular machinery involved in efferocytosis have opened many avenues for therapeutic intervention, with several agents now in clinical trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-022-00470-y

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Efferocytosis in other settings can promote fibrosis as part of tissue resolution, for example, by secreting TGF-β1.

    “efferocytosis in other settings can promote fibrosis as part of the tissue resolution process, for example, by secreting TGF-β1 (12, 13).”

    From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [13]

    The Digestion phase says efferocytosis-associated signalling increases macrophage TGFβ expression, and the Cancer section describes possible TGFβ release by macrophages engulfing apoptotic cells. These passages support the secretion mechanism, but they do not say that efferocytosis promotes fibrosis during tissue resolution or identify the cytokine specifically as TGF-β1. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • No approaches targeting efferocytosis have thus far been clinically approved.

    “While some progress has been made with respect to the Fractalkine receptor (CX3C motif chemokine receptor 1), Axl, MerTK, CD47 and Tim4/3, no approaches have thus far been clinically approved (64).”

    From Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells (2026) · cites this paper as [64]

    Table 1 (Approaches to target the eating phase; page unavailable) lists therapeutics targeting Axl, MerTK, CD47 and TIM4/3 as being in clinical trials, supporting the distinction between progress in trials and clinical approval. The Introduction (page unavailable) also says an autologous apoptotic-cell approach is already in use. The review does not establish the broader claim that no approach targeting efferocytosis has been clinically approved. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Accumulation of dead cells in disease indicates impaired clearance by macrophages.

    “The accumulation of dead cells in disease settings indicates impaired clearance of dead cells by macrophages (“efferocytosis”) (12, 13).”
  • Efferocytosis prevents dead cell accumulation and reprograms macrophages for tissue resolution, and its impairment contributes to many chronic inflammatory diseases.

    “Efferocytosis not only prevents dead cell accumulation but also reprograms macrophages to execute tissue resolution functions, and impaired efferocytosis contributes to many human chronic inflammatory diseases (12, 13).”
  • Efferocytosis is seen as a major hurdle to using antigen presenting cells in cell-based therapies.

    “It is seen as a major hurdle to using antigen presenting cells in cell-based therapies (61–64).”

    From Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells (2026) · cites this paper as [64]

    The Cancer section describes efferocytosis as a challenge for antitumour drug development, and the Infectious diseases section reports reduced antigen presentation by dendritic cells in a specific infection. Neither passage addresses whether efferocytosis is a major hurdle to using antigen-presenting cells in cell-based therapies. Searches for antigen-presenting cells and cell-based therapies found no passage making that connection. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 3

  1. [23]Urbani, L. et al. in Transplantation Proceedings 1175–1178 (Elsevier, 2004).
  2. [116]Dalli J Colas R Shinohara M Serhan CN Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving Medicines 2014 193 4235 4244 PMC4185223 25217168
  3. [192]Noelia A Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR Immunity 2009 31 245 258 10.1016/j.immuni.2009.06.018 19646905 PMC2791787 · DOI

Cited by

Sorted by citations

Authors
Mehrotra, P., & Ravichandran, K. S.
Affiliations
  • VIB-UGent Center for Inflammation Research (BE)
  • Washington University in St. Louis (US)
Corresponding author
Ravichandran, Kodi S.
Venue
Nature Reviews Drug Discovery
Published
2022-06-01
Volume
21
Issue
8
Pages
601-620
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W4281737563
Cited by
459
References
231
Citations by year
2026: 130 · 2025: 153 · 2024: 104 · 2023: 66 · 2022: 6
FWCI
8.88
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute (P01HL120840)
  • National Institute of General Medical Sciences (R35GM122542)
  • National Institute of Allergy and Infectious Diseases (R01AI159551)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
efferocytosis, phagocytes, anti-inflammatory mechanism, inflammation resolution, therapeutic target, atherosclerosis, cancer, infection
MeSH terms
Homeostasis, Humans, Phagocytes, Phagocytosis, Apoptosis, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review